Assessment of different biomarkers provides valuable diagnostic standards in the evaluation of the risk of acute rejection  

作　　者：Jin Zheng Xiaoming Ding Xiaohui Tian Zhankui Jin Xiaoming Pan Hang Yan Xinshun Feng Jun Hou Heli Xiang Li Ren Puxun Tian Wujun Xue 

机构地区：[1]Hospital of Nephropathy,The First Affiliated Hospital of Medical College,Xi'an Jiaotong University,Xi'an 710061,China

出　　处：《Acta Biochimica et Biophysica Sinica》2012年第9期730-736,共7页生物化学与生物物理学报（英文版）

基　　金：This work was supported by grants fi＇om the 13115 Innovation Technology Project of Special Purpose of Shanxi Province （2087ZDKG-67）;and the National Natural Science Foundation of China （30772096）.

摘　　要：Acute rejection （AR） is a strong risk factor for chronic rejection in renal transplant recipients. Accurate and timely diagnosis of AR episodes is very important for disease control and prognosis. Therefore, objectively evaluated the immune status of patients is essential in the field of post- transplantation treatment. This longitudinal study investigated the usefulness of five biomarkers, human leukocyte antigen （HLA）-G5 and sCD30 level in sera, intracellular ad- enosine triphosphate （iATP） release level of CD4＋ T cells, and granzyme B/perforin expression in peripheral blood mononuclear cells （PBMCs） and biopsies, to detect AR and the resolution of biomarkers in a total of 84 cases of renal transplantation. The data demonstrated that recipients with clinical or biopsy proven rejection significantly increased iATP release level of CD4＋ T cells, and elevated sCD30 but lowered HLA-G5 level in sera compared with individuals with stable graft function. Expression levels of granzyme B and perforin were also elevated in PBMCs and graft biopsies of AR patients. Taken together, we identified that upregulation of sCD30, iATP, granzyme B, perforin, and downregulation of HLA-G5 could provide valuable diagnostic standards to identify those recipients in the risk of AR. And iATP may be a better biomarker than others for predicting the graft rejection episode.Acute rejection （AR） is a strong risk factor for chronic rejection in renal transplant recipients. Accurate and timely diagnosis of AR episodes is very important for disease control and prognosis. Therefore, objectively evaluated the immune status of patients is essential in the field of post- transplantation treatment. This longitudinal study investigated the usefulness of five biomarkers, human leukocyte antigen （HLA）-G5 and sCD30 level in sera, intracellular ad- enosine triphosphate （iATP） release level of CD4＋ T cells, and granzyme B/perforin expression in peripheral blood mononuclear cells （PBMCs） and biopsies, to detect AR and the resolution of biomarkers in a total of 84 cases of renal transplantation. The data demonstrated that recipients with clinical or biopsy proven rejection significantly increased iATP release level of CD4＋ T cells, and elevated sCD30 but lowered HLA-G5 level in sera compared with individuals with stable graft function. Expression levels of granzyme B and perforin were also elevated in PBMCs and graft biopsies of AR patients. Taken together, we identified that upregulation of sCD30, iATP, granzyme B, perforin, and downregulation of HLA-G5 could provide valuable diagnostic standards to identify those recipients in the risk of AR. And iATP may be a better biomarker than others for predicting the graft rejection episode.

关 键 词：renal transplant acute rejection HLA-G5 SCD30 iATP 

分 类 号：Q347[生物学—遗传学] P618.130.1[天文地球—矿床学]